The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates

Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

Bernard Escudier, Tim Eisen, Walter M. Stadler et al. · New England Journal of Medicine · 2007 · 4.8K citations · Full text

Medicine, Nephrology, Oncology +11

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Scott M. Wilhelm, Christopher Carter, LiYa Tang et al. · Cancer Research · 2004 · 4K citations · Full text

Medicine, Oncology, Pharmacology +17

Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.

Emil J. Freireich, E. A. Gehan, David P. Rall et al. · PubMed · 1966 · 1.4K citations

Pharmacy, Oncology, Toxicology +14

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

Dirk Strumberg, Heike Richly, Ralf A. Hilger et al. · Journal of Clinical Oncology · 2004 · 871 citations · Full text

Medicine, Oncology, Pharmacology +16

Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Tumors

Jeffrey W. Clark, Joseph P. Eder, David P. Ryan et al. · Clinical Cancer Research · 2005 · 338 citations

Medicine, Oncology, Pharmacology +17